Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis [1]

Scandinavian Journal of Rheumatology

Volumn 35, Issue 4, 2006, Pages 322-323

  Martinez Taboada V M ^a   Val Bernal, J F ^a   Pesquera, L C ^b   Fernandez Llanio N E ^a   Esteban, J M P ^a   Blanco, R ^a   Alonso Bartolome, P ^a   Gonzalez Vela, C ^a   Rodriguez Valverde V ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Clinica Mompia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LENERCEPT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; CASE REPORT; CLINICAL TRIAL; DEMYELINATING DISEASE; DIPLOPIA; ERYTHEMA; FEMALE; HEADACHE; HUMAN; INJECTION SITE REACTION; LETTER; LYMPHOCYTIC VASCULITIS; MULTIPLE SCLEROSIS; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY; VASCULITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DEMYELINATING DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; VASCULITIS, ALLERGIC CUTANEOUS;

EID: 33746802332     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740600557249     Document Type: Letter

References (10)

1. Moreland LW, Baumgartner SW, Schiff MH, Tyndall EA, Fleischman RM, Weaver AL, et al. Treatment of rheumatoid arthritis with recombinant tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
2. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 2003;32:312-14.
3. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomised, placebo-controlled multicenter study. Neurology 1999;53:457-65.
4. Kunzmann S, Warmuth-Metz M, Girschick HJ. Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand J Rheumatol 2005;34:76-8.
5. Wyeth-Ayerst Laboratories and Immunex Inc. [Revised package insert for etanercept.] 2000.
6. Mohan N, Edwards ET, Cupps TR, Oliveiro PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
7. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8.
8. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. By what mechanisms could tumor necrosis factor α antagonists improved rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Schwid SR, Noseworthy JH. Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology 1999;53:444-5.